Edgewise Therapeutics (EWTX) Share-based Compensation (2020 - 2026)

Edgewise Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $8.7 million in Q1 2026.

• Quarterly Share-based Compensation fell 3.8% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (down 70.46% YoY) and the FY2025 annual result came in at $64.9 million, up 15.69% from the prior year.
• Share-based Compensation improved to $8.7 million in Q1 2026 per EWTX's latest filing, from -$17.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $9.1 million in Q1 2025 and troughed at -$17.1 million in Q4 2025.
• A 5-year average of $2.7 million and a median of $3.8 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation plunged 402.38% in 2023, then jumped 4987.1% in 2024.
• Over 5 years, Share-based Compensation stood at $3.7 million in 2022, then slumped by 402.38% to -$11.3 million in 2023, then jumped by 168.48% to $7.7 million in 2024, then sank by 320.71% to -$17.1 million in 2025, then soared by 151.04% to $8.7 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $8.7 million, -$17.1 million, and $8.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.